Author:
Lang Gabriele E.,Berta András,Eldem Bora M.,Simader Christian,Sharp Dianne,Holz Frank G.,Sutter Florian,Gerstner Ortrud,Mitchell Paul
Reference12 articles.
1. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration;Ferrara;Retina,2006
2. European Medicines Agency. Lucentis: EPAR-Product Information. EMEA/H/C/000715-IB/0032. Updated July 20, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed February 1, 2013.
3. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema;Diabetic Retinopathy Clinical Research Network;Ophthalmology,2010
4. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema;Diabetic Retinopathy Clinical Research Network Writing Committee;Ophthalmology,2011
5. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study;Massin;Diabetes Care,2010
Cited by
110 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献